Clinical Trial

Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

Recruiting
View on ClinicalTrials.gov →
Summary
This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-06-19; most recent amendment 2026-03-30.
Status change: Not Yet Recruiting → Recruiting 2024-06-25
Trial Details
NCT Number NCT06474533
Lead Sponsor Thomas Hope
Conditions Intracranial Neoplasm
Enrollment 199 participants
Start Date 2024-06-21
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-03